AbbVie Inc. (TSX:ABBV)

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue	46.60B	43.03B
United States Revenue Growth	8.31%	2.74%
International Revenue	14.56B	13.31B
International Revenue Growth	9.41%	7.00%
Revenue (Total)	61.16B	56.33B
Revenue (Total) Growth	8.57%	3.71%

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Immunology Revenue	30.41B	26.68B
Immunology Revenue Growth	13.96%	2.09%
Neuroscience Revenue	10.77B	9.00B
Neuroscience Revenue Growth	19.65%	16.61%
Oncology Revenue	6.66B	6.56B
Oncology Revenue Growth	1.53%	10.82%
Aesthetics Revenue	4.86B	5.18B
Aesthetics Revenue Growth	-6.11%	-2.23%
Eye Care Revenue	2.11B	2.24B
Eye Care Revenue Growth	-5.93%	-7.16%
Other Key Products Revenue	3.74B	3.65B
Other Key Products Revenue Growth	2.41%	-4.15%
All Other Revenue	2.63B	3.03B
All Other Revenue Growth	-13.36%	-0.10%
Revenue (Total)	61.16B	56.33B
Revenue (Total) Growth	8.57%	3.71%

Updated Dec 31, 2025. Data Source: Fiscal.ai.